In July 2010 Verisante Technology (OTCQX:VRSEF) entered a licensing agreement with British Columbia's BC Cancer Agency for use of their cancer detection technology in order to accelerate development of their cancer detection device program. Initial commercialization of the device is focused on the detection of skin cancer, with extensions of the product expected to follow for the detection of other cancers, including lung, gastro-intestinal and cervical.
Skin cancer is a relatively common disease, the incidence of which is on the rise. Since melanoma is progressive and usually fatal in later stages, early detection and removal of cancerous skin lesions is critical to improve patient outcomes. Verisante's patented Aura device has been designed to do just that.
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: